Anthony J. Jaslowski
Expertise in
51
conditions

Dr. Anthony J. Jaslowski

Hematology | Oncology | Internal Medicine
3501 Ludington Street, 
Escanaba, MI 
On Staff At
Expertise in
51
conditions
3501 Ludington Street, 
Escanaba, MI 

Overview

Anthony Jaslowski is a Hematologist and an Internal Medicine provider practicing medicine in Escanaba, Michigan.

Dr. Jaslowski is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Colorectal Cancer, Bone Marrow Aspiration, and Myringotomy.

Dr. Jaslowski is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 40 clinical trials.

Graduate Institution

Loyola University Of Chicago, No Value Specified, 1987

Residency

Wilford Hall Medical Center, USAF, Internal Medicine, 1990

Specialties

Hematology
Oncology
Internal Medicine

Licenses

Internal Medicine in WI

Board Certifications

American Board Of Internal Medicine

Fellowships

Wilford Hall Medical Center, USAF, Medical Oncology, 1993

Hospital Affiliations

Ascension Ne Wisconsin - St Elizabeth Campus
St Marys Hospital Medical Ctr
Door County Medical Center
St Vincent Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

OSF HealthCare Daniel J. Kobasic Cancer Clinic
3501 Ludington Street, Escanaba, MI 49829

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

39 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.
Journal: Journal for immunotherapy of cancer
Published: January 20, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Ross Siemers
Hematology | Oncology
Expertise in
19
conditions
Dr. Ross Siemers
Hematology | Oncology

Marquette General Hospital

1414 W Fair Ave Ste 332, 
Marquette, MI 
 (143.4 miles away)
906-225-3922
Languages Spoken:
English
See accepted insurances

Ross Siemers is a Hematologist and an Oncologist practicing medicine in Marquette, Michigan. Dr. Siemers is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Myelogenous Leukemia (CML).

Expertise in
17
conditions
Dr. Edgard A. Badine
Hematology | Oncology | Internal Medicine
Expertise in
17
conditions
Dr. Edgard A. Badine
Hematology | Oncology | Internal Medicine

OSF HealthCare Daniel J. Kobasic Cancer Clinic

3501 Ludington Street, 
Escanaba, MI 
 (96.6 miles away)
906-233-4140
Languages Spoken:
English, Arabic, French
See accepted insurances

Edgard Badine is a Hematologist and an Internal Medicine provider practicing medicine in Escanaba, Michigan. Dr. Badine is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Pancreatoblastoma, Pleuropulmonary Blastoma, Lung Cancer, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Badine is board certified in American Board Of Internal Medicine.

Expertise in
16
conditions
Dr. Bradley C. Heraly
Hematology | Oncology | Internal Medicine
Expertise in
16
conditions
Dr. Bradley C. Heraly
Hematology | Oncology | Internal Medicine

OSF HealthCare Daniel J. Kobasic Cancer Clinic

3501 Ludington Street, 
Escanaba, MI 
 (96.6 miles away)
906-233-4140
Languages Spoken:
English
See accepted insurances

Bradley Heraly is a Hematologist and an Internal Medicine provider practicing medicine in Escanaba, Michigan. Dr. Heraly is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Leukocytosis, Colorectal Cancer, Familial Colorectal Cancer, Hemochromatosis, and Bone Marrow Aspiration. Dr. Heraly is board certified in American Board Of Internal Medicine.

Frequently Asked Questions about Dr. Anthony J. Jaslowski

How do I make an appointment with Dr. Anthony J. Jaslowski?

You can book an appointment with Dr. Anthony J. Jaslowski by calling their office at 906-233-4140. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anthony J. Jaslowski a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anthony J. Jaslowski is classified as an Distinguished expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anthony J. Jaslowski specialize in?

While Dr. Anthony J. Jaslowski is a Hematology, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Anthony J. Jaslowski participate in research or clinical trials?

Yes. Dr. Anthony J. Jaslowski has published 11 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Anthony J. Jaslowski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anthony J. Jaslowski accept my insurance?

Dr. Anthony J. Jaslowski accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 906-233-4140 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jaslowski's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 37 Advanced Conditions
    View All 151 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile